Skip to main content

Table 2 Clinical and pathological data summaries in both training and testing cohort

From: Two-dimensional and three-dimensional T2 weighted imaging-based radiomic signatures for the preoperative discrimination of ovarian borderline tumors and malignant tumors

Ā 

Training group (Nā€‰=ā€‰99)

Testing group (Nā€‰=ā€‰97)

P value

Age (yrs.)

45.9ā€‰Ā±ā€‰13.35

46.64ā€‰Ā±ā€‰15.90

0.961

ā€‰ <ā€‰30

17(17.2%)

14(14.4%)

Ā 

Ā 30ā€“50

35(35.4%)

40(41.2%)

Ā 

ā€‰ >ā€‰50

47(47.5%)

43(44.3%)

Ā 

Ki-67 expression (%)

32.37ā€‰Ā±ā€‰28.01

25.05ā€‰Ā±ā€‰26.35

0.946

Ā ā€‰<ā€‰50

59(67.0%)

74(84.1%)

Ā 

Ā 50ā€“75

20(22.7%)

5(5.7%)

Ā 

ā€‰ >ā€‰75

9(10.2%)

9(10.2%)

Ā 

CA-125 level(IU/L)

553.32ā€‰Ā±ā€‰994.28

300.30ā€‰Ā±ā€‰452.27

0.000

ā€‰ <ā€‰35

15(22.7%)

18(27.7%)

Ā 

Ā 35ā€“200

17(25.8%)

24(36.9%)

Ā 

Ā 200ā€“500

13(19.7%)

10(15.4%)

Ā 

Ā ā€‰>ā€‰500

21(31.8%)

13(20.0%)

Ā 

Category

Ā Ā 

0.980

Ā Borderline tumor

47(47.5%)

44(45.4%)

Ā 

Ā Malignancies

52(52.5%)

53(54.6%)

Ā 

Ā Endometroid cancer

2(2.0%)

1(1.0%)

Ā 

Ā Low-grade adenocarcinoma

0(0.0%)

3(3.1%)

Ā 

Ā Clear cell type

1(1.%)

4(4.1%)

Ā 

Ā Serous carcinoma

45(45.5%)

38(39.2%)

Ā 

Ā Mucinous carcinoma

2(2.0%)

5(5.2%)

Ā 

Ā Mixed carcinoma

2(2.0%)

2(2.1%)

Ā